source
- Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trialTango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
- Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisitionNovo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…